Regeneron Pharmaceuticals, Inc. · NASDAQ:REGN

Regeneron Pharmaceuticals — Technical Presentation (February 2024)

22 slides from Regeneron Pharmaceuticals's technical presentation, February 2024

  1. Slide 1: Impact of Retinal Neurodegenerative Changes in Patients with DME from the VISTA Study

    Impact of Retinal Neurodegenerative Chan in Patients with Diabetic Macular Edema from the VISTA Study Dilraj S Grewal MD on behalf of the VISTA and VIVID study investigators Duke University School of Medicine, Durham, North Carolina Presented at the Macula Society Annual Meeting, February 7—’

  2. Slide 2: Disclosures

    Disclosures ¢ Dilraj S Grewal is a consultant for EyePoint, Priovant, lvericBio, Regeneron Pharmaceuticals, Inc., and Unity ¢ This analysis was funded by Regeneron Pharmaceuticals, Inc. (Tarrytown, New York), who is the sponsor and participated in the design and conduct of the study, analysis of the

  3. Slide 3: Background and Objectives

    Background and Objectives * Retinal thickness measured by OCT has limited predictive value for visual acuity in patients with DR and DME'2 ¢ DRIL represents a potential structural biomarker for loss of visual function in DR, and has been associated with worse visual acuity, increased RNP, disease se

  4. Slide 4: VISTA Study Design

    VISTA Study Design Randomized, multicenter, double-masked trial in patients with clinically significant DME, central involvement and ETDRS BCVA 20/40 to 20/320 Randomized and treated: N=466 ¥ Patients randomized 1:1:1 IAI 2q8" ~~ Laser control Primary endpoint: mean change in BCVA Co ued treatment t

  5. Slide 5: Methods

    Methods * Extent of DRIL, ELM loss, and EZ loss were quantified as microns in the central 1000-um macular area based on OCT images at baseline and Weeks 52 and 100 by Duke Reading Center * Outcomes evaluated at Weeks 52 and 100: 1. Changes in markers of retinal neurodegeneration over time 2. Correla

  6. Slide 6: 1. Changes in Markers of Retinal Neurodegeneration Over Time

    1. Changes in Markers of Retinal Neurodegeneration Over Time

  7. Slide 7: DRIL Extent

    DRIL Extent Through Week 100 Mean DRIL Extent Mean Change in DRIL Extent from Baseline mBaseline mWeek 52 im Week 100 m Week 52 m Week 100 300 262 120 5 £ ef = Sw 804 ¢ éc 38 § &% % 200 2 40 | 10 = 2i = or 0 a re n= 93 89 c os | ar 100 ze —40 = oC = s 2G go | 52 3 =32 -73 = a -84 o} -120 J 102 Laser

  8. Slide 8: Proportion of Eyes with Changes in DRIL from Baseline

    Proportion of Eyes with Changes in DRIL from Baseline Through Week 100 Laser (n=154) IAI 2q4 (n=154) IAI 2q8 (n=151) Week 52 ™ Improved Hl No change MM) Worsened Mi Missi Week 100 BEING FAS, OC.

  9. Slide 9: Extent of ELM Loss

    Extent of ELM Loss Through Week 100 Mean Extent of ELM Loss Mean Change in Extent of ELM Loss from Baseline mBaseline mWeek52 mWeek 100 m Week 52 m= Week 100 200 £ ty 7 144 a & is 5 134 S85 80 ~~ ao 5 & 5 2 40 KG 34 oF oy 79 Bay ine 105 105 95 97 as eu = 2s a) a 6 -12 -9 <a $2 46 48 Ow 40 oe Ww 40 —

  10. Slide 10: Proportion of Eyes with Changes in ELM Loss from Baseline

    Proportion of Eyes with Changes in ELM Loss Week 52 Week 100 FAS, OC. from Baseline Through Week 100 Laser (n=154) IAI 294 (n=154) IAI 2q8 (n=151) ™ Improved Hl No change MM) Worsened HB Missing

  11. Slide 11: Extent of EZ Loss

    Extent of EZ Loss Through Week 100 Mean Extent of EZ Loss Mean Change in Extent of EZ Loss from Baseline mBaseline mWeek 52 m Week 100 m Week 52 m= Week 100 360 2 120 89 270 3 300 247 QE 3 57 5 5s n o_o 5 2 40 BE 200} 1% We Be As aaa 136 Bg f= 105 104 9495 i % 150 116 a) on 2 94 97 oe -=N vc -40 = i

  12. Slide 12: Proportion of Eyes with Changes in EZ Loss from Baseline

    Proportion of Eyes with Changes in EZ Loss from Week 52 Week 100 Baseline Through Week 100 Laser (n=154) IAI 2q4 (n=154) IAI 2q8 (n=151) ™ Improved Hl No change MM) Worsened HB Missing FAS, OC.

  13. Slide 13: 2. Correlation Between Markers of Retinal Neurodegeneration and Visual and Anatomic Parameters

    2. Correlation Between Markers of Retinal Neurodegeneration and Visual and Anatomic Parameters

  14. Slide 14: Correlations between Markers of Retinal Neurodegeneration and BCVA, CST, DRSS, RNP at Baseline

    Correlations between Markers of Retinal Neurodegeneration and BCVA, CST, DRSS score, and RNP at Baseline: All Treatment Groups Combined Strength of correlation: Weak (r $0.39) Moderate (r = 0.4-0.69)|__ Strong (r>0.7) DRIL 1 ELM Loss EZ Loss (n=334) BCVA DRSS RNP FAS, OC. Correlation between extent

  15. Slide 15: Correlations Between Markers of Retinal Neurodegeneration and BCVA, DRSS Score and RNP

    Correlations Between Markers of Retinal Neurodegeneration and BCVA, DRSS Score and RNP Through Week 100 Strength of correlation: Weak (r $0.39) Moderate ( 69) Strong (r>0.7) 0.50 (97) Week 52 (n=89) 0.47 0) ) =28) (n=77) 0.50 . E 0.79 0.81 ) (n=77) (n=77) 0.56 0.53 (n=47) ) ( (n=77) 0.03 Week 100 (n

  16. Slide 16: 3. Changes in Retinal Neurodegeneration Markers by Baseline BCVA ≥20/40 Versus ≤20/50

    3. Changes in Retinal Neurodegeneration Markers by Baseline BCVA ≥20/40 Versus ≤20/50

  17. Slide 17: Magnitude of Difference in Retinal Neurodegeneration by Baseline BCVA

    Week 52 Week 100 Magnitude of Difference in Retinal Neurodegeneration in Eyes with Baseline BCVA 220/40 Versus $20/50 Laser n IAI 2q4 n IAI 2q8 n 1 52.2 95.3 -706 —— So +e 220/40 (172.2, 67.9) i (141.1, 49.5)" a5 od (-145.3, 4.1) © -223.2 (401.2, -45.2)4 100.3 (184.8, -15.9)4 26 —o— 220/140. +——®—+

  18. Slide 18: 4. DRIL, ELM Loss, and EZ Loss by Their Respective Baseline Extent

    4. DRIL, ELM Loss, and EZ Loss by Their Respective Baseline Extent

  19. Slide 19: DRIL Extent by Baseline DRIL Tertile

    DRIL Extent Through Week 100 by Baseline DRIL Tertile Laser Combined IAI mBaseline mWeek 52 m Week 100 mBaseline mWeek 52 mWeek 100 = 500 E & ¢ = 400 Leo ao ov £ 2g 4 rf g S300 s 2 233 ir a a 180 183 2 200 or im 126 a a 83 s g 100 38 44 35 oO ov = = of min GS is : : n=37 29 29 37 33° 29 37 31 31 n=7

  20. Slide 20: Extent of ELM Loss by Baseline ELM Loss Subgroup

    Extent of ELM Loss Through Week 100 by Baseline ELM Loss Subgroup Laser Combined IAI mBaseline mWeek 52 = Week 100 500 400 oy i=) t=) Mean (SE) extent of ELM loss, pm N 8 n= 77 64 62 No ELM loss ELM loss Mean (SE) extent of ELM loss, ym 500 400 roy i=) t=) mBaseline mWeek 52 m Week 100 251 161 0 5 1

  21. Slide 21: Extent of EZ Loss by Baseline EZ Loss Subgroup

    Extent of EZ Loss Through Week 100 by Baseline EZ Loss Subgroup Laser Combined IAI mBaseline mWeek 52 = Week 100 mBaseline mWeek 52 m Week 100 500 5 500 5 398 i} i) 2 400 4 2 400 4 g £ g £ 309 B jy 300 5 B yy 300 5 =o — oO m4 i 3 212 ca a= 02 >wN 200 4 407 >wN 200 4 gu 112 gu vo o = 100 5 = 100 + 0

  22. Slide 22: Conclusion

    Conclusion * At Weeks 52 and 100, in patients with DME: — Those treated with IAI had greater improvement in DRIL and better preservation of EZ and ELM compared with laser — Across all treatment groups, DRIL, ELM loss, and EZ loss had a moderate negative correlation with BCVA, and weak correlations w

Regeneron Pharmaceuticals — Technical Presentation (February 2024) on 6ix